AI assistant
ACADIA PHARMACEUTICALS INC — Director's Dealing 2011
Jun 14, 2011
31237_dirs_2011-06-14_18f09601-3331-4f27-9de5-6dcf42519738.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ACADIA PHARMACEUTICALS INC (ACAD)
CIK: 0001070494
Period of Report: 2011-06-10
Reporting Person: Iversen Leslie L (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2011-06-10 | Stock option (right to buy) | $1.75 | A | 10000 | Acquired | 2021-06-09 | Common stock (10000) | Direct |
| 2011-06-10 | Stock option (right to buy) | $1.75 | A | 38571 | Acquired | 2021-06-09 | Common stock (38571) | Direct |
| 2011-06-10 | Stock option (right to buy) | $1.75 | A | 6000 | Acquired | 2021-06-09 | Common Stock (6000) | Direct |
Footnotes
F1: 25% of the shares subject to the Stock Option vest and become exercisable at the end of each 3-month period following the date of grant.
F2: The Reporting Person has elected to convert annual retainer fees of $22,500 into a stock option under the terms of the Issuer's Outside Director Compensation Program.
F3: 25% of the shares subject to the Stock Option vest 1 year after the date of grant, with 1/48th of the shares vesting after each the following 36 months.
F4: Stock option awarded under the terms of the Issuer's Outside Director Compensation Program for service on the Issuer's Scientific Advisory Committee.